Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia

被引:24
作者
Chen, Yi-Hua
Peterson, LoAnn C.
Dittmann, David
Evens, Andrew
Rosen, Steven
Khoong, Adela
Shankey, T. Vincent
Forman, Meryl
Gupta, Rohit
Goolsby, Charles L.
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Diagnost Mol Biol Lab, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Internal Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] John H Stroger Jr Hosp Cook Cty, Dept Pathol, Chicago, IL USA
[5] Adv Technol Ctr, Beckman Coulter, Miami, FL USA
关键词
ZAP-70; flow cytometry; chronic lymphocytic leukemia; IgV(H) gene;
D O I
10.1309/230199FLE32ATUB0
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
We compared I subjective and 5 objective flow cytometric methods to evaluate zeta-associated protein (ZAP-70) expression in relation to immunoglobulin heavy-chain variable-region (IgV(H)) gene mutational status in 154 samples from 125 patients with chronic lymphocytic leukemia (CLL). ZAP-70 expression determined by all methods used correlated with IgV(H) gene mutational status, but none of them demonstrated high concordance rates. Of the objective methods, ZAP-70 staining determined as a ratio of molecules of equivalent soluble fluorochrome intensity in CLL cells to that in normal B cells (ZAP-70+ staining in IgV(H) germline cases, 59%; Z4P-70- in IgV(H) mutated cases, 75%) or T cells (Z4P-70+ in IgV(H) germline cases, 66%; ZAP-70- in IgV(H) mutated cases, 57%) provides the best combination for assigning ZAP-70+ status to IgV(H) germline and ZAP-70- status to IgV(H) mutated 9 cases. The subjective method based on ZAP-70 expression in natural killer/T cells gave a similar result, but reproducibility between laboratories may be difficult. Further studies on Z4P-70 expression in relation to clinical parameters may address whether Z4P-70 is an independent prognostic marker for CLL.
引用
收藏
页码:182 / 191
页数:10
相关论文
共 38 条
[1]
[Anonymous], 1999, J Natl Cancer Inst, V91, P861
[2]
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[3]
2-V
[4]
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].
Byrd, JC ;
Peterson, BL ;
Morrison, VA ;
Park, K ;
Jacobson, R ;
Hoke, E ;
Vardiman, JW ;
Rai, K ;
Schiffer, CA ;
Larson, RA .
BLOOD, 2003, 101 (01) :6-14
[5]
ZAP-70 directly enhances TgM signaling in chronic lymphocytic leukemia [J].
Chen, LG ;
Apgar, J ;
Huynh, L ;
Dicker, F ;
Giago-McGahan, T ;
Rassenti, L ;
Weiss, A ;
Kipps, TJ .
BLOOD, 2005, 105 (05) :2036-2041
[6]
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia [J].
Chen, LG ;
Widhopf, G ;
Huynh, L ;
Rassenti, L ;
Rai, KR ;
Weiss, A ;
Kipps, TJ .
BLOOD, 2002, 100 (13) :4609-4614
[7]
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].
Crespo, M ;
Bosch, F ;
Villamor, N ;
Bellosillo, B ;
Colomer, D ;
Rozman, M ;
Marcé, S ;
López-Guillermo, A ;
Campo, E ;
Montserrat, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775
[8]
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847
[9]
Davis B, 2004, CYTOM PART B-CLIN CY, V62B, P62
[10]
When and how to treat chronic lymphocytic leukemia. [J].
Dighiero, G ;
Binet, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (24) :1799-1801